home / stock / vstm / vstm quote
Last: | $9.215 |
---|---|
Change Percent: | 1.93% |
Open: | $9.13 |
Close: | $9.215 |
High: | $9.38 |
Low: | $9.02 |
Volume: | 71,062 |
Last Trade Date Time: | 04/25/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$9.215 | $9.13 | $9.215 | $9.38 | $9.02 | 71,062 | 04-25-2024 |
$9.31 | $9.54 | $9.31 | $9.75 | $9.27 | 78,623 | 04-24-2024 |
$9.61 | $9.68 | $9.61 | $9.93 | $9.58 | 101,447 | 04-23-2024 |
$9.74 | $9.84 | $9.74 | $10 | $9.671 | 95,499 | 04-22-2024 |
$9.84 | $10.1 | $9.84 | $10.355 | $9.56 | 151,397 | 04-19-2024 |
$10.23 | $10.89 | $10.23 | $11.02 | $10.19 | 66,842 | 04-18-2024 |
$10.84 | $10.9 | $10.84 | $11.18 | $10.77 | 54,337 | 04-17-2024 |
$10.93 | $11.03 | $10.93 | $11.49 | $10.93 | 64,334 | 04-16-2024 |
$11.07 | $11.3 | $11.07 | $11.34 | $10.935 | 117,053 | 04-15-2024 |
$11.3 | $11.76 | $11.3 | $11.77 | $11.1 | 85,312 | 04-12-2024 |
$11.81 | $11.27 | $11.81 | $11.815 | $11.12 | 75,924 | 04-11-2024 |
$11.3 | $11.5 | $11.3 | $11.66 | $11.12 | 92,040 | 04-10-2024 |
$11.74 | $12.09 | $11.74 | $12.26 | $11.5988 | 124,297 | 04-09-2024 |
$11.86 | $11.42 | $11.86 | $11.98 | $11.275 | 138,457 | 04-08-2024 |
$11.44 | $11.18 | $11.44 | $11.81 | $10.86 | 88,187 | 04-05-2024 |
$11.33 | $11.95 | $11.33 | $12.186 | $11.29 | 84,183 | 04-04-2024 |
$11.98 | $11.58 | $11.98 | $12.02 | $11.35 | 103,845 | 04-03-2024 |
$11.52 | $11.67 | $11.52 | $11.86 | $11.39 | 87,114 | 04-02-2024 |
$11.73 | $11.86 | $11.73 | $12.05 | $11.4 | 118,539 | 04-01-2024 |
$11.8 | $11.79 | $11.8 | $12.1 | $11.675 | 98,806 | 03-29-2024 |
News, Short Squeeze, Breakout and More Instantly...
Dr. Hayslip to lead development programs for avutometinib, including Verastem Oncology’s international confirmatory Phase 3 RAMP 301 clinical trial, and advance pipeline assets Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for ...
Findings presented at SGO 2024 show 87% of respondents afraid of making long-term plans due to the possibility of a shorter life expectancy 84% say dealing with treatment side effects has negatively impacted their emotional well-being, and 94% worry about LGSOC returning despite treatment...
Initiated confirmatory Phase 3 RAMP 301 trial evaluating avutometinib and defactinib combination in recurrent low-grade serous ovarian cancer; on track to submit rolling NDA for accelerated approval in H1 2024; preparations underway for potential commercial launch in 2025 Granted FDA Fast...